Based on these results, a phase II clinical trial, ‘Clinical study of anti-CD147 humanized meplazumab for injection to treat with 2019-nCoV pneumonia’ (ClinicalTrials.gov Identifier: NCT04275245) [75], to test the inhibitory effect of anti-CD147 antibodies is currently underway. The gene discussed is BSG; the disease is susceptibility to pneumonia measurement.